NCT02298959: Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors

NCT02298959
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase
Exclusions: Patients with untreated unknown brain metastases or carcinomatous meningitis- see trial for details
https://ClinicalTrials.gov/show/NCT02298959

Comments are closed.

Up ↑